tickrz reports
Pfizer Inc (PFE)
Healthcare | Drugs
35.72  -0.06%
PFE vs DRUGS SECTOR & S&P 500
VALUATION
PFESECTORS&P 500
P/E RATIO22.013820.18
EV/EBITDA RATIO12.84121.612.15
P/S RATIO4.116.22.14
P/B RATIO3.557.33.29
QUALITY
RETURN ON EQUITY15.79%15.79%13.65%
RETURN ON CAPITAL12.55%19.38%10.09%
NET MARGIN13.63%14.46%9.76%
DIVIDEND ANALYSIS
DIVIDEND YIELD
3.58%
PAYOUT RATIO76.89%
3 YR DIVIDEND GROWTH7.57%
FINANCIAL STRENGTH
PIOTROSKI F SCORE
6 OUT OF 9
DEBT-TO-EQUITY72%
INTEREST COVERAGE10.9x
CURRENT RATIO1.43
GROWTH
5 YR EPS GROWTH1.13%
5 YR SPS GROWTH-4.14%
5 YR BPS GROWTH-1.99%
About tickrz
Key Concepts
Great Investors
tickrz Report
FACTOR RANKINGSFACTOR SCREENER 
TICKRZ MFM RANK C / 264PURE VALUE RANKC / 262
DIVIDEND RANKD / 356MOAT RANKC / 309
FINANCIAL STRENGTH RANKB / 159GROWTH RANKD / 417
MOMENTUM RANKB / 217
tickrz MFM rank C / 264
Pfizer Inc receives a C ranking in our multi-factor model that blends valuation, moat, operational performance, and financial strength. View the tickrz MFM Screener here.
value
pure value ranking C / 262Warren Buffett ranking B / 232
Valuation is the most heavily weighted component in our tickrz ranking methodology. Numerous academic and practitioner studies have found that a value approach outperforms the market over the long-run. Pfizer Inc's valuation score is comprised of a P/E ratio of 22x, a P/B ratio of 3.6x, a P/S ratio of 4.1x, and an EV/EBITDA ratio of 12.8x. Pfizer Inc ranks 262 out of the S&P 500 constituents on valuation--a relatively weak score.Pfizer Inc ranks 232 out of the S&P 500 constituents in our multi-factor Warren Buffett ranking methodology. This is a average score, meaning it ranks in the middle of the pack on valuation, moat, volatility, and financial strength factors. If you're looking for undervalued stocks with high moats and strong competitive advantages, Pfizer Inc is probably not for you.

quality
moat C / 309financial strength B / 159
To calculate a company's Moat Score, we look at its historical earnings growth, historical average return on equity, the volatility of its earnings stream, and also factor in the strength of its balance sheet. Our approach concludes the company's business moat is weak. Its position within the Healthcare sector appears to be weak. Either the dynamics of its sector place it in a difficult position or management's executition is to blame for its disappointing performance.Pfizer Inc has a Piotroski F Score of 6 out of 9. The F Score examines changes in profitability, leverage, liquidity, and operating efficiency. Interest coverage of 10.9x, a debt/equity ratio of 72% and a Moat Rank of 309 translate to an average Financial Strength score.


momentum B / 217
Investment research has shown that stocks with strong performance over the last 6 to 12 months tend to perform better in the medium term than stocks with poor performance over the same period. In fact, the momentum factor is one of the strongest of all the investment factors. The company has seen its stock appreciate by 14.22% over the last 12 months. This performance is average compared to other stocks in the S&P 500, earning it a rank of 217. Based on its 12 month stock performance, Pfizer Inc will not appeal to momentum investors.

yield D / 356
value + yield
Shares currently yield 3.58%. Our dividend ranking approach looks at a company's dividend growth rate, payout ratio, business moat, and valuation. Based on our methodology, Pfizer Inc ranks 356 among the S&P 500 constituents. Investors looking for undervalued dividend stocks will probably want to look elsewhere.

growth D / 417
A company's growth metrics are less important than its valuation, moat, and financial strength. However, a check on growth can be a good way to avoid companies in secular decline. The company's growth in sales, earnings, and book value places it among the bottom third of S&P500 companies. Its 1.1% 5 year annualized EPS growth, -4.1% 5 year annualized sales-per-share growth, and 5 year annualized book value-per-share growth of -2% speak to its relatively poor ranking.

Pfizer Inc (PFE)
Healthcare | Drugs
35.72  -0.06%


tickrz rank
C
VALUATION RATIOS
P/E Ratio22.01x
P/B Ratio3.55x
P/S Ratio4.11x
EV/EBITDA Ratio12.84x
DIVIDEND ANALYSIS
DIVIDEND YIELD
3.58%
PAYOUT RATIO76.89%
3 YR DIVIDEND GROWTH7.57%
FINANCIAL STRENGTH
PIOTROSKI F SCORE
6 OUT OF 9
DEBT-TO-EQUITY72%
INTEREST COVERAGE10.9x
CURRENT RATIO1.43
MOAT
ROE15.79%
ROIC12.55%
Net Margin13.63%
GROWTH
5 YR EPS GROWTH1.13%
5 YR SPS GROWTH-4.14%
5 YR BPS GROWTH-1.99%

TICKRZ RANK
Pfizer Inc receives a C ranking in our multi-factor model that blends valuation, moat, operational performance, and financial strength. View the tickrz MFM Screener here.

PURE VALUE
Valuation is the most heavily weighted component in our tickrz ranking methodology. Numerous academic and practitioner studies have found that a value approach outperforms the market over the long-run. Pfizer Inc's valuation score is comprised of a P/E ratio of 22x, a P/B ratio of 3.6x, a P/S ratio of 4.1x, and an EV/EBITDA ratio of 12.8x. Pfizer Inc ranks 262 out of the S&P 500 constituents on valuation--a relatively weak score.

WARREN BUFFETT RANKING
Pfizer Inc ranks 232 out of the S&P 500 constituents in our multi-factor Warren Buffett ranking methodology. This is a average score, meaning it ranks in the middle of the pack on valuation, moat, volatility, and financial strength factors. If you're looking for undervalued stocks with high moats and strong competitive advantages, Pfizer Inc is probably not for you.

MOAT
To calculate a company's Moat Score, we look at its historical earnings growth, historical average return on equity, the volatility of its earnings stream, and also factor in the strength of its balance sheet. Our approach concludes the company's business moat is weak. Its position within the Healthcare sector appears to be weak. Either the dynamics of its sector place it in a difficult position or management's executition is to blame for its disappointing performance.

FINANCIAL STRENGTH
Pfizer Inc has a Piotroski F Score of 6 out of 9. The F Score examines changes in profitability, leverage, liquidity, and operating efficiency. Interest coverage of 10.9x, a debt/equity ratio of 72% and a Moat Rank of 309 translate to an average Financial Strength score.

MOMENTUM
Investment research has shown that stocks with strong performance over the last 6 to 12 months tend to perform better in the medium term than stocks with poor performance over the same period. In fact, the momentum factor is one of the strongest of all the investment factors. The company has seen its stock appreciate by 14.22% over the last 12 months. This performance is average compared to other stocks in the S&P 500, earning it a rank of 217. Based on its 12 month stock performance, Pfizer Inc will not appeal to momentum investors.

VALUE + YIELD
Shares currently yield 3.58%. Our dividend ranking approach looks at a company's dividend growth rate, payout ratio, business moat, and valuation. Based on our methodology, Pfizer Inc ranks 356 among the S&P 500 constituents. Investors looking for undervalued dividend stocks will probably want to look elsewhere.

GROWTH
A company's growth metrics are less important than its valuation, moat, and financial strength. However, a check on growth can be a good way to avoid companies in secular decline. The company's growth in sales, earnings, and book value places it among the bottom third of S&P500 companies. Its 1.1% 5 year annualized EPS growth, -4.1% 5 year annualized sales-per-share growth, and 5 year annualized book value-per-share growth of -2% speak to its relatively poor ranking.